Financial Comparison of Small-Cap Healthcare Companies INMED and CorMedix
1 report, 1 independent
Updated Oct 22
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
A comparison of INMED and CorMedix showed that CorMedix has higher revenue and earnings compared to INMED. INMED is trading at a lower price-to-earnings ratio, making it appear more affordable. Furthermore, CorMedix has higher institutional ownership (34.2%) than INMED (20.1%).
From themarketsdaily.com
Why it matters
The comparison provides insight into the risk and valuation profiles of these two small-cap healthcare companies. INMED has a lower beta of 0.93, suggesting its share price is less volatile than the S&P 500, while CorMedix has a beta of 1.4.
From themarketsdaily.com
Who's involved
- INMEDSmall-cap healthcare company whose stock trades on the Nasdaq.
- MarketBeatAmerican personal finance blog that provides ratings and price targets for INMED.
- SECSlovak company with which INMED filed an S-4 registration statement regarding a merger.
- HeronCompany in Austria noted as a peer to INMED in the small-cap healthcare sector.
- NasdaqAmerican fully electronic stock exchange where INMED is listed and trading.
Keep exploring
The entities involved
-
INMED
organization
Nothing else this week.